Informing a target product profile for rapid tests to identify HBV-infected pregnant women with high viral loads: a discrete choice experiment with African healthcare workers

  1. Isa, Yasir Shitu
  2. Sicsic, Jonathan
  3. Njuguna, Henry
  4. Ward, John
  5. Chakroun, Mohamed
  6. El-Kassas, Mohamed
  7. Ramanampamonjy, Rado
  8. Chalal, Salim
  9. Vincent, Jeanne Perpétue
  10. Andersson, Monique
  11. Desalegn, Hailemichael
  12. Fall, Fatou
  13. Johannessen, Asgeir
  14. Matthews, Philippa C.
  15. Ndow, Gibril
  16. Okeke, Edith
  17. Riches, Nicholas
  18. Seydi, Moussa
  19. Sinkala, Edford
  20. Spearman, C. Wendy
  21. Stockdale, Alexander
  22. Vinikoor, Michael J.
  23. Wandeler, Gilles
  24. Sombié, Roger
  25. Lemoine, Maud
  26. Mueller, Judith E.
  27. Shimakawa, Yusuke ORCID logo

Download
s12916-023-02939-y.pdf 1,44MB
WeightNameValue
1000 Titel
  • Informing a target product profile for rapid tests to identify HBV-infected pregnant women with high viral loads: a discrete choice experiment with African healthcare workers
1000 Autor/in
  1. Isa, Yasir Shitu |
  2. Sicsic, Jonathan |
  3. Njuguna, Henry |
  4. Ward, John |
  5. Chakroun, Mohamed |
  6. El-Kassas, Mohamed |
  7. Ramanampamonjy, Rado |
  8. Chalal, Salim |
  9. Vincent, Jeanne Perpétue |
  10. Andersson, Monique |
  11. Desalegn, Hailemichael |
  12. Fall, Fatou |
  13. Johannessen, Asgeir |
  14. Matthews, Philippa C. |
  15. Ndow, Gibril |
  16. Okeke, Edith |
  17. Riches, Nicholas |
  18. Seydi, Moussa |
  19. Sinkala, Edford |
  20. Spearman, C. Wendy |
  21. Stockdale, Alexander |
  22. Vinikoor, Michael J. |
  23. Wandeler, Gilles |
  24. Sombié, Roger |
  25. Lemoine, Maud |
  26. Mueller, Judith E. |
  27. Shimakawa, Yusuke |
1000 Erscheinungsjahr 2023
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2023-07-04
1000 Erschienen in
1000 Quellenangabe
  • 21(1):243
1000 Copyrightjahr
  • 2023
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12916-023-02939-y |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10320875/ |
1000 Ergänzendes Material
  • https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-023-02939-y#Sec17 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Elimination of mother-to-child transmission of hepatitis B virus (HBV) requires infant immunoprophylaxis and antiviral prophylaxis for pregnant women with high viral loads. Since real-time polymerase chain reaction (RT-PCR), a gold standard for assessing antiviral eligibility, is neither accessible nor affordable for women living in low-income and middle-income countries (LMICs), rapid diagnostic tests (RDTs) detecting alternative HBV markers may be needed. To inform future development of the target product profile (TPP) for RDTs to identify highly viremic women, we used a discrete choice experiment (DCE) and elicited preference and trade-off of healthcare workers (HCW) in Africa between the following four attributes of fictional RDTs: price, time-to-result, diagnostic sensitivity, and specificity. METHODS: Through an online questionnaire survey, we asked participants to indicate their preferred test from a set of two RDTs in seven choice tasks with varying levels of the four attributes. We used mixed multinomial logit models to quantify the utility gain or loss generated by each attribute. We attempted to define minimal and optimal criteria for test attributes that can satisfy ≥ 70% and ≥ 90% of HCWs, respectively, as an alternative to RT-PCR. RESULTS: A total of 555 HCWs from 41 African countries participated. Increases in sensitivity and specificity generated significant utility and increases in cost and time-to-result generated significant disutility. The size of the coefficients for the highest attribute levels relative to the reference levels were in the following order: sensitivity (β = 3.749), cost (β = -2.550), specificity (β = 1.134), and time-to-result (β = -0.284). Doctors cared most about test sensitivity, while public health practitioners cared about cost and midwives about time-to-result. For an RDT with 95% specificity, costing 1 US$, and yielding results in 20 min, the minimally acceptable test sensitivity would be 82.5% and the optimally acceptable sensitivity would be 87.5%. CONCLUSIONS: African HCWs would prefer an RDT with the following order of priority: higher sensitivity, lower cost, higher specificity, and shorter time-to-result. The development and optimization of RDTs that can meet the criteria are urgently needed to scale up the prevention of HBV mother-to-child transmission in LMICs.
1000 Sacherschließung
lokal Target product file
lokal Elimination
lokal Preferences
lokal Mother-to-child transmission
lokal Africa
lokal Hepatitis B
lokal Discrete choice experiment
lokal Rapid diagnostic test
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/SXNhLCBZYXNpciBTaGl0dQ==|https://frl.publisso.de/adhoc/uri/U2ljc2ljLCBKb25hdGhhbg==|https://frl.publisso.de/adhoc/uri/Tmp1Z3VuYSwgSGVucnk=|https://frl.publisso.de/adhoc/uri/V2FyZCwgSm9obg==|https://frl.publisso.de/adhoc/uri/Q2hha3JvdW4sIE1vaGFtZWQ=|https://frl.publisso.de/adhoc/uri/RWwtS2Fzc2FzLCBNb2hhbWVk|https://frl.publisso.de/adhoc/uri/UmFtYW5hbXBhbW9uanksIFJhZG8=|https://frl.publisso.de/adhoc/uri/Q2hhbGFsLCBTYWxpbQ==|https://frl.publisso.de/adhoc/uri/VmluY2VudCwgSmVhbm5lIFBlcnDDqXR1ZQ==|https://frl.publisso.de/adhoc/uri/QW5kZXJzc29uLCBNb25pcXVl|https://frl.publisso.de/adhoc/uri/RGVzYWxlZ24sIEhhaWxlbWljaGFlbA==|https://frl.publisso.de/adhoc/uri/RmFsbCwgRmF0b3U=|https://frl.publisso.de/adhoc/uri/Sm9oYW5uZXNzZW4sIEFzZ2Vpcg==|https://frl.publisso.de/adhoc/uri/TWF0dGhld3MsIFBoaWxpcHBhIEMu|https://frl.publisso.de/adhoc/uri/TmRvdywgR2licmls|https://frl.publisso.de/adhoc/uri/T2tla2UsIEVkaXRo|https://frl.publisso.de/adhoc/uri/UmljaGVzLCBOaWNob2xhcw==|https://frl.publisso.de/adhoc/uri/U2V5ZGksIE1vdXNzYQ==|https://frl.publisso.de/adhoc/uri/U2lua2FsYSwgRWRmb3Jk|https://frl.publisso.de/adhoc/uri/U3BlYXJtYW4sIEMuIFdlbmR5|https://frl.publisso.de/adhoc/uri/U3RvY2tkYWxlLCBBbGV4YW5kZXI=|https://frl.publisso.de/adhoc/uri/VmluaWtvb3IsIE1pY2hhZWwgSi4=|https://frl.publisso.de/adhoc/uri/V2FuZGVsZXIsIEdpbGxlcw==|https://frl.publisso.de/adhoc/uri/U29tYmnDqSwgUm9nZXI=|https://frl.publisso.de/adhoc/uri/TGVtb2luZSwgTWF1ZA==|https://frl.publisso.de/adhoc/uri/TXVlbGxlciwgSnVkaXRoIEUu|http://orcid.org/0000-0002-4198-4785
1000 Label
1000 Förderer
  1. Wellcome |
  2. University College London Hospitals Biomedical Research Centre |
1000 Fördernummer
  1. 110110/Z/15/Z
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Wellcome |
    1000 Förderprogramm -
    1000 Fördernummer 110110/Z/15/Z
  2. 1000 joinedFunding-child
    1000 Förderer University College London Hospitals Biomedical Research Centre |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6453009.rdf
1000 Erstellt am 2023-07-05T10:20:54.000+0200
1000 Erstellt von 337
1000 beschreibt frl:6453009
1000 Bearbeitet von 317
1000 Zuletzt bearbeitet 2023-08-02T13:42:07.144+0200
1000 Objekt bearb. Wed Aug 02 13:41:49 CEST 2023
1000 Vgl. frl:6453009
1000 Oai Id
  1. oai:frl.publisso.de:frl:6453009 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source